CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results